ArticleCell discovery2018
Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells.
Article in Cell discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Inducible dCas12a system expands CRISPRi/a capabilities for functional genomics in malaria parasiteiScience · 2026Article
- A systematic screening assay identifies efficient small guide RNAs for CRISPR activation.Frontiers in bioengineering and biotechnology · 2025Article
- Single-Nucleotide Microbial Genome Editing Using CRISPR-Cas12a.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Systematic optimization of Cas12a base editors in wheat and maize using the ITER platform.Genome biology · 2023Article
- Quantitative and modularized CRISPR/dCas9-dCpf1 dual function system inFrontiers in bioengineering and biotechnology · 2023Article
- Efficient Single-Nucleotide Microbial Genome Editing Achieved Using CRISPR/Cpf1 with Maximally 3'-End-Truncated crRNAs.ACS synthetic biology · 2022Article
- Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.BMC biology · 2022Article
- New insights on CRISPR/Cas9-based therapy for breast Cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- CRISPR-Cas Activators for Engineering Gene Expression in Higher Eukaryotes.The CRISPR journal · 2020Review
- CRISPR Cpf1 proteins: structure, function and implications for genome editing.Cell & bioscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cpf1, an RNA-guided DNA endonuclease that belongs to a new class II CRISPR system, has recently been harnessed for genome editing. Herein, we report an RNase-resistant caged truncated pre-tRNA-like crRNA (catRNA) that confers precise and efficient gene editing with the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.